AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9848888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg BID for 12 weeks
Number of subjects: 189
Study 8055741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 35
Study 8055741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3180108 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dexfenfluramine (d‐FF)
Number of subjects: 13
Study 3180108 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg metergoline (MTG)
Number of subjects: 13
Study 3180108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3180108 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐FF
Number of subjects: 13
Study 31879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Salud al Día intervention (educational video and interactive text messages)
Number of subjects: 157
Study 29253560 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination (reduced 2 + 1 or licensed 3 + 1 schedule)
Number of subjects: 851
Study 29253560 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 4CMenB dose in follow-on participants
Number of subjects: 851
Study 29253560 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 catch-up doses in vaccine-naïve participants
Number of subjects: 851
Study 29253560 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB vaccination (2 + 1 or 3 + 1 schedule)
Number of subjects: 851
Study 29253560 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated schedule in vaccine-naïve children
Number of subjects: 851
Study 27343784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P, n=25)
Number of subjects: 100
Study 27343784 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg gabapentin (Group G400, n=25)
Number of subjects: 100
Study 27343784 — intervention group
Group type: EXPERIMENTAL
Intervention: 800mg gabapentin (Group G800, n=25)
Number of subjects: 100
Study 27343784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200mg gabapentin (Group G1200, n=25)
Number of subjects: 100
Study 24469705 — intervention group
Group type: EXPERIMENTAL
Intervention: Stemmed prosthesis
Number of subjects: 19
Study 24469705 — intervention group
Group type: COMPARATOR
Intervention: Stemless prosthesis
Number of subjects: 19
Study 22071384 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark
Number of subjects: 164
Study 22071384 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Japan
Number of subjects: 164
Study 22071384 — intervention group
Group type: COMPARATOR
Intervention: BCG-Russia
Number of subjects: 164
Study 20609970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial Technosphere inhaled insulin plus bedtime insulin glargine
Number of subjects: 677
Study 20609970 — intervention group
Group type: COMPARATOR
Intervention: Twice daily premixed biaspart insulin
Number of subjects: 677
Study 19317948 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 0.5 mg/kg/d
Number of subjects: 160
Study 19317948 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 1.5 mg/kg/d
Number of subjects: 160
Study 19317948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 15578195 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG or Lactobacillus acidophilus CRL431)
Number of subjects: 64
Study 15578195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chemically acidified clotted milk without bacteria)
Number of subjects: 64
Study 11879248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux (LF) hemodialysis for 8 weeks
Number of subjects: 25
Study 11879248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux (HF) hemodialysis for 8 weeks
Number of subjects: 25
Study 11879248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of HF hemodialysis (first 8 weeks of Group Y + second 8 weeks of Group X)
Number of subjects: 25
Study 11879248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of LF hemodialysis (first 8 weeks of Group X + second 8 weeks of Group Y)
Number of subjects: 25
Study 11879248 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of variance for Hct and dialysis membrane permeability
Number of subjects: 25
Study 10929962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise
Number of subjects: 59
Study 10929962 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 59
Study 8607952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.25% bupivacaine hydrochloride infiltrated around each tonsil
Number of subjects: 19
Study 8607952 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo (normal saline) infiltration
Number of subjects: 19
Study 8607952 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study 1333934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (8 mg)
Number of subjects: 12
Study 1333934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (16 mg)
Number of subjects: 12
Study 1333934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1333934 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 12
Study 1333934 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (20 mg)
Number of subjects: 12
Study 6365107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantethine (300 mg t.i.d.) in type IIB patients
Number of subjects: 29
Study 6365107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantethine (first treatment) in type IIB patients
Number of subjects: 29
Study 6365107 — intervention group
Group type: COMPARATOR
Intervention: Pantethine (preceded by placebo) in type IIB patients
Number of subjects: 29
Study 6365107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantethine (first treatment) in type IV patients
Number of subjects: 29
Study 6365107 — intervention group
Group type: COMPARATOR
Intervention: Pantethine (preceded by placebo) in type IV patients
Number of subjects: 29
Study 6365107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantethine in type IV patients
Number of subjects: 29
Study 6365107 — intervention group
Group type: COMPARATOR
Intervention: Switching from Pantethine to placebo
Number of subjects: 29
Study 6365107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantethine in type IIB patients
Number of subjects: 29
Study 30794649 — intervention group
Group type: EXPERIMENTAL
Intervention: Women taking oral contraceptives
Number of subjects: 45
Study 30794649 — intervention group
Group type: EXPERIMENTAL
Intervention: Women not taking oral contraceptives
Number of subjects: 45
Study 30794649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of women
Number of subjects: 45
Study 30794649 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-left cognitive control task
Number of subjects: 45
Study 29194198 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod (LBN) 0.024% once daily (qd)
Number of subjects: 840
Study 29194198 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily (bid)
Number of subjects: 840
Study 26707996 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 10 mg daily for 7 days
Number of subjects: 19
Study 26707996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25163399 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (VAS)
Number of subjects: 232
Study 25163399 — intervention group
Group type: COMPARATOR
Intervention: Oral polio vaccine (OPV0)
Number of subjects: 232
Study 21801101 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous whole blood (AWB) injections
Number of subjects: 88
Study 21801101 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) injections
Number of subjects: 88
Study 21801101 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 88
Study 19919597 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 1493
Study 19919597 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual with Assessment (TAU+)
Number of subjects: 1493
Study 17362845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinfrontal
Number of subjects: 113
Study 17362845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 15661431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (60 and 120 ng/mL)
Number of subjects: 11
Study 15661431 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 11
Study 11757473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide-5-mononitrate (IS-5-MN) 100 mg/day
Number of subjects: 40
Study 11757473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9404745 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI through a 750‐mL cone‐shaped spacer (2 puffs) and nebulized salbutamol aerosol 0.5 mL in 1.5 mL saline solution (group 1, n=25)
Number of subjects: 50
Study 9404745 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI and 0.5 mL saline solution in 1.5 mL saline solution (group 2, n=25)
Number of subjects: 50
Study 8355156 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm incision with Staar AA‐4203 silicone intraocular lens
Number of subjects: 151
Study 8355156 — intervention group
Group type: COMPARATOR
Intervention: 5.5 mm incision with loptex 5 mm x 6 mm oval optic lens
Number of subjects: 151
Study 8355156 — intervention group
Group type: COMPARATOR
Intervention: 6.5 mm incision with AMO three‐piece modified C‐loop lens
Number of subjects: 151
Study 2826548 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyes' method of non‐surgical therapy
Number of subjects: 9
Study 2826548 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap surgery
Number of subjects: 9
Study 2695437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclane
Number of subjects: 19
Study 2695437 — intervention group
Group type: COMPARATOR
Intervention: Buflomedil
Number of subjects: 19
Study 31115309 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth physician-patient interviews informed by Health Belief Model constructs
Number of subjects: 18
Study 31115309 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and nasopharyngeal/oralpharyngeal specimens analysis using TaqMan Array Cards for multipathogen detection
Number of subjects: 18
Study 29340488 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP10 (CPAP at 10 cmH2O)
Number of subjects: 13
Study 29340488 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP5 (CPAP at 5 cmH2O)
Number of subjects: 13
Study 29340488 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 13
Study 25979532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube removal at drainage volume of less than 300 ml/day (Group B)
Number of subjects: 168
Study 25979532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube removal at drainage volume of less than 450 ml/day (Group C)
Number of subjects: 168
Study 25979532 — intervention group
Group type: COMPARATOR
Intervention: Chest tube removal at drainage volume of 150 ml/day or less (Group A)
Number of subjects: 168
Study 25979532 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracentesis incidence in Group C
Number of subjects: 168
Study 25979532 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinsertion of chest drains among the three groups
Number of subjects: 168
Study 24074360 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 250 mg/day
Number of subjects: 60
Study 24074360 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 500 mg/day
Number of subjects: 60
Study 24074360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24074360 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 M/M genotype
Number of subjects: 60
Study 24074360 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 I/I genotype
Number of subjects: 60
Study 21663597 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0
Study 21663597 — intervention group
Group type: COMPARATOR
Intervention: Social skills training (Control)
Number of subjects: 0
Study 19373239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 48
Study 17008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented progressive resistance strength training (4 weeks)
Number of subjects: 48
Study 17008338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation training)
Number of subjects: 48
Study 15564358 — intervention group
Group type: EXPERIMENTAL
Intervention: Social evaluation condition (n = 41)
Number of subjects: 81
Study 15564358 — intervention group
Group type: COMPARATOR
Intervention: No social evaluation condition (n = 40)
Number of subjects: 81
Study 11394950 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite physical exercise intervention (9 months, supervised, twice a week)
Number of subjects: 87
Study 11394950 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite physical exercise intervention
Number of subjects: 87
Study 11394950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 9402118 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 81
Study 9402118 — intervention group
Group type: COMPARATOR
Intervention: Bipolar probe
Number of subjects: 81
Study 8354136 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice daily (group 1)
Number of subjects: 24
Study 8354136 — intervention group
Group type: COMPARATOR
Intervention: 300 mg aspirin daily (group 2)
Number of subjects: 24
Study 3304956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate 1600 mg daily
Number of subjects: 40
Study 3304956 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine 10 mg daily
Number of subjects: 40
Study 31883526 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weekly sessions of non-specialist-delivered Interpersonal Psychotherapy (IPT)
Number of subjects: 2710
Study 31883526 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of fluoxetine prescribed by a nurse or clinical officer
Number of subjects: 2710
Study 31883526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (IPT and fluoxetine)
Number of subjects: 2710
Study 31883526 — intervention group
Group type: COMPARATOR
Intervention: IPT
Number of subjects: 2710
Study 31883526 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 2710
Study 28256406 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 40
Study 28256406 — intervention group
Group type: COMPARATOR
Intervention: Partial splenic artery embolisation (PSE)
Number of subjects: 40
Study 26311640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 µg every 6 hours for a maximum of 4 doses after 200 mg oral mifepristone
Number of subjects: 625
Study 26311640 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol 400 µg every 3 hours for a maximum of 4 doses after 200 mg oral mifepristone
Number of subjects: 625
Study 23498354 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised dynamic sling training
Number of subjects: 5
Study 23498354 — intervention group
Group type: COMPARATOR
Intervention: Traditional unsupervised lumbar stabilization home exercise program (HEP)
Number of subjects: 5
Study 21375163 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phacoemulsification with dual infusion technique through irrigating chopper
Number of subjects: 200
Study 21375163 — intervention group
Group type: COMPARATOR
Intervention: Conventional phaco surgery
Number of subjects: 200
Study 19687610 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive health education and hot spa bathing, 2-hour program every 2 weeks for 24 weeks, plus individualized programs once a week.
Number of subjects: 43
Study 19687610 — intervention group
Group type: COMPARATOR
Intervention: General health guidance (Control group).
Number of subjects: 43
Study 16799345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol
Number of subjects: 29
Study 16799345 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anesthesia with isoflurane
Number of subjects: 29
Study 16799345 — intervention group
Group type: COMPARATOR
Intervention: Both anesthetic techniques (propofol and isoflurane)
Number of subjects: 29
Study 15259288 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen plus medroxyprogesterone acetate (CE/MPA 0.625 mg/5 mg)
Number of subjects: 249
Study 15259288 — intervention group
Group type: COMPARATOR
Intervention: 17beta‐estradiol plus norethisterone acetate (E2/NETA 2 mg/1 mg)
Number of subjects: 249
Study 15259288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CE/MPA and E2/NETA
Number of subjects: 249
Study 15259288 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/MPA 0.625 mg/5 mg
Number of subjects: 249
Study 15259288 — intervention group
Group type: EXPERIMENTAL
Intervention: History of premenstrual syndrome (PMS)
Number of subjects: 249
Study 11334726 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin 85 mg/m(2) every 2 weeks
Number of subjects: 73
Study 11334726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with 5-FU 425 mg/m(2)/day and FA 20 mg/m(2)/dayx5 days every 4 weeks
Number of subjects: 73
Study 9234925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 plus carboplatin 350 mg/m2
Number of subjects: 173
Study 9234925 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 1000 mg/m2 plus cisplatin 80 mg/m2
Number of subjects: 173
Study 8438781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine meals per day
Number of subjects: 19
Study 8438781 — intervention group
Group type: COMPARATOR
Intervention: Three meals per day
Number of subjects: 19
Study 2445151 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg nickel (nickel sulphate)
Number of subjects: 146
Study 2445151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg cobalt (cobalt sulphate)
Number of subjects: 146
Study 2445151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 2445151 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 146
Study 30993587 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) at doses of 1.8 or 2.4 mg/kg once every three weeks
Number of subjects: 63
Study 30993587 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 63
Study 28042070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (FEC100→taxane) ± bevacizumab
Number of subjects: 84
Study 25867783 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smartphone self-monitoring (n = 34)
Number of subjects: 50
Study 25867783 — intervention group
Group type: COMPARATOR
Intervention: Biweekly Web-survey only (n = 16)
Number of subjects: 50
Study 23713407 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release triamcinolone and lidocain injection
Number of subjects: 36
Study 23713407 — intervention group
Group type: COMPARATOR
Intervention: Saline and lidocain injection
Number of subjects: 36
Study 21475252 — intervention group
Group type: EXPERIMENTAL
Intervention: LDAC + ATO (0.25 mg/kg on days 1-5, 9, and 11 for at least four courses every 4 to 6 weeks)
Number of subjects: 166
Study 21475252 — intervention group
Group type: COMPARATOR
Intervention: LDAC (20 mg b.d. for 10 days)
Number of subjects: 166
Study 18641209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (100 mg L-theanine + 50 mg caffeine)
Number of subjects: 0
Study 18641209 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone (50 mg)
Number of subjects: 0
Study 18641209 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine alone (100 mg)
Number of subjects: 0
Study 18641209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16947448 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking barefoot
Number of subjects: 75
Study 16947448 — intervention group
Group type: COMPARATOR
Intervention: Everyday walking shoes
Number of subjects: 75
Study 12915959 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium skimmed milk (50 g daily, containing 1200 mg calcium)
Number of subjects: 200
Study 12915959 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 200
Study 10632100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (DCP)
Number of subjects: 73
Study 10632100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8731105 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of acidosis (bicarbonate)
Number of subjects: 7
Study 8731105 — intervention group
Group type: COMPARATOR
Intervention: Acidosis (acid)
Number of subjects: 7
Study 1474173 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate, 100 mg
Number of subjects: 24
Study 1474173 — intervention group
Group type: EXPERIMENTAL
Intervention: meclizine, 50 mg
Number of subjects: 24
Study 1474173 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 1474173 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 24
Study 1474173 — intervention group
Group type: EXPERIMENTAL
Intervention: meclizine
Number of subjects: 24
Study 6386032 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial radiotherapy as an adjunct to topical therapy
Number of subjects: 15
Study 6386032 — intervention group
Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 15
Study 31064805 — intervention group
Group type: EXPERIMENTAL
Intervention: PAL training delivered to teachers over two after-school sessions.
Number of subjects: 321
Study 29448833 — intervention group
Group type: EXPERIMENTAL
Intervention: luseogliflozin 2.5 mg
Number of subjects: 233
Study 29448833 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 233
Study 25532501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641
Study 23886432 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM-SLIT
Number of subjects: 22
Study 23886432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22